All News

2020

April

Media Release / Apr 02, 2020

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

Read More
Media Release / Apr 02, 2020

Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo

Read More

March

Media Release / Mar 28, 2020

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

Read More
Media Release / Mar 27, 2020

Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

Read More
Media Release / Mar 27, 2020

AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Read More
Media Release / Mar 26, 2020

Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

Read More
Media Release / Mar 24, 2020

Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing

Read More
Media Release / Mar 24, 2020

AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2

Read More
Media Release / Mar 20, 2020

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response

Read More
Media Release / Mar 19, 2020

Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More